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Abstract
Objectives: To characterize via NMR spectroscopy the full spectrum of metabolic changes in umbilical vein blood
plasma of newborns diagnosed with different clinical forms of intrauterine growth restriction (IUGR).
Methods: 23 early IUGR cases and matched 23 adequate-for-gestational-age (AGA) controls and 56 late IUGR
cases with 56 matched AGAs were included in this study. Early IUGR was defined as a birth weight <10th centile,
abnormal umbilical artery (UA) Doppler and delivery <35 weeks. Late IUGR was defined as a birth weight <10th
centile with normal UA Doppler and delivery >35 weeks. This group was subdivided in 18 vasodilated (VD) and 38
non-VD late IUGR fetuses. All AGA patients had a birth weight >10th centile. 1H nuclear magnetic resonance (NMR)
metabolomics of the blood samples collected from the umbilical vein at delivery was obtained. Multivariate statistical
analysis identified several metabolites that allowed the discrimination between the different IUGR subgroups, and
their comparative levels were quantified from the NMR data.
Results: The NMR-based analysis showed increased unsaturated lipids and VLDL levels in both early and late IUGR
samples, decreased glucose and increased acetone levels in early IUGR. Non-significant trends for decreased
glucose and increased acetone levels were present in late IUGR, which followed a severity gradient when the VD
and non-VD subgroups were considered. Regarding amino acids and derivatives, early IUGR showed significantly
increased glutamine and creatine levels, whereas the amounts of phenylalanine and tyrosine were decreased in early
and late-VD IUGR samples. Valine and leucine were decreased in late IUGR samples. Choline levels were
decreased in all clinical subforms of IUGR.
Conclusions: IUGR is not associated with a unique metabolic profile, but important changes are present in different
clinical subsets used in research and clinical practice. These results may help in characterizing comprehensively
specific alterations underlying different IUGR subsets.
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Introduction
Intrauterine growth restriction (IUGR) affects 7-10% of all
pregnancies [1] and is defined by the underachievement of the
genetic growth potential in the fetus. IUGR is associated with
an increased risk for adverse perinatal outcome [2–4] and long
term fetal programming in the form of cardiovascular disease,
metabolic syndrome and neurological deficits [5–8]. The early-
onset forms of IUGR represent the most severe [6,9] but less
prevalent presentation of this condition. Early-onset IUGR is
consistently associated with abnormalities in feto-placental
Doppler and with severe placental insufficiency [10–12]. Late-
onset forms of IUGR, -also referred to as small for gestational
age (SGA) [2]-, are far more prevalent than early IUGR, but
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they represent a more heterogeneous condition. While, as a
whole, late-onset IUGR is associated with signs of placental
injury and poorer perinatal outcome [13], there are important
individual differences in the feto-placental Doppler response
and a proportion of these fetuses present with relatively normal
perinatal outcomes. There is general agreement that it is likely
that different causes may lead to late-onset IUGR [14] and that
part of late IUGR fetuses are merely constitutionally small [15].
However, clinical clues to differentiate specific groups within
this diagnostic category are still scarce. Research over recent
years has demonstrated that a subgroup of late-onset IUGR
have signs of increased brain perfusion as measured by middle
cerebral artery (MCA) Doppler [16].This subset has
consistently been reported to present poorer perinatal outcome
[16–19]. In contrast, fetuses with normal brain Doppler have
similar outcomes when compared to fetuses with normal
growth [16,19]. Since brain vasodilation is a response to
hypoxia [20], it has been suggested that late IUGR fetuses with
increased brain perfusion represent milder forms of a “late-
onset placental disease” group with milder but similar features
to early-IUGR fetuses [16,21]. However, there are no grounds
to support these assumptions. In addition, it is unknown
whether those SGA fetuses with no Doppler changes in brain
circulation are merely milder forms of the same disease,
whether they are constitutionally small fetuses, or whether they
represent another pathogenic pathway leading to abnormally
low fetal growth.
Metabolomics is considered a powerful approach to study
the multivariate metabolic responses to physiological and/or
pathological stressors, providing integrative information about
patterns of disease [22–24]. Recently, two studies reported that
the metabolic blood profiles of IUGR newborns express
significant differences in glucose and amino acid metabolic
levels in comparison with controls [25,26]. However, the
specific metabolomic patterns of the different clinical forms of
IUGR have not been investigated. We hypothesized that
metabolomics could be helpful in elucidating whether there are
pathophysiological differences behind the above described
IUGR subsets.
The aim of this prospective study was to characterize the full
spectrum of metabolic changes in cord blood plasma of
newborns diagnosed with different clinical forms of IUGR. We
used a metabolomics approach based on 1H-NMR
spectroscopy. Three clinical groups of early-onset IUGR, late-
onset IUGR with normal brain Doppler and late-onset IUGR
with Doppler signs of vasodilation were recruited and
compared with matched normally grown neonates.
Materials and Methods
This study was conducted at the Maternofetal Medicine
Research Group, Hospital Clinic, Barcelona Spain and at the
Centro de Investigación Príncipe Felipe, Valencia, Spain. The
study protocol was approved by the Hospital Clinic of
Barcelona ethics committee and all patients that were included
for this study provided a written informed consent for their
inclusion in the study and the blood obtained from their
neonates as their legal guardians. IRB (2012/7684)
Study populations
The study design was a prospective cohort study that
included 79 cases diagnosed with IUGR (23 early and 56 late
IUGR) and 79 control subjects (23 matched for early IUGR and
56 for late IUGR) with a birth weight appropriate for gestational
age. Pregnancies were dated by the first-trimester crown-rump
length measurement [27]. Patients that were enrolled in this
study were identified before delivery from singleton
pregnancies by performing a detailed ultrasound-Doppler
assessment within one week before delivery. In all study
participants full prenatal information was available. Our sample
was classified in early and late IUGR defined as an estimated
and confirmed birth weight below the 10th centile according to
local standards [28]. Additional defining criteria for early IUGR
fetuses: 1) Gestational age at birth 34 weeks or less; 2)
Umbilical artery Doppler pulsatility index (PI) >95th centile [29]
in at least two consecutive examinations 24 hours apart. Late
IUGR neonates were also defined by: 1) Gestational age at
delivery equal or above 35 weeks; 2) Normal umbilical artery
Doppler PI (below 95th centile) [29]. Late IUGR samples were
divided into two subgroups: Vasodilated late-IUGR if they
presented a MCA PI value <5th centile [30] in at least two
consecutive examinations 24 hours apart and non-vasodilated
late IUGR cases if their MCA PI was >5th centile. Control
subjects were singleton appropriate-for-gestational-age (AGA)
fetuses (birth weight >10th centile according to local standards
[28]) that were matched with cases by gestational age at
delivery (± 7 days) and gender. Subjects were considered non-
eligible in the presence of any of the following: Congenital
malformations or chromosomal defects, congenital infections,
clinical chorioamnionitis or maternal disease such as
autoimmune disease or the presence of cardiovascular risk
factors such as diabetes mellitus, pregestational dyslipidemia
or BMI >35.
Clinical and Ultrasound parameters
All IUGR fetuses underwent a detailed anatomical and
Doppler examination. Prenatal Doppler parameters such as
umbilical artery PI and MCA PI were prospectively recorded.
Prenatal Doppler ultrasound examinations were performed
using a Siemens Sonoline Antares scanner (Siemens medical
systems, Malvern, PA, USA) and a 6-2 MHz linear-curved-
array transducer. Spectral Doppler parameters were obtained
automatically from three or more consecutive waveforms with
the angle of insonation as close to zero as possible. Umbilical
artery PI was obtained on a free floating cord loop. MCA PI
was obtained in a transversal view of the fetal head, at its origin
from the circle of Willis.
The administration of oral or endovenous maternal drugs two
weeks before or at delivery was recorded in all IUGR cases
and controls.
Samples
500 µl of blood was obtained from the umbilical vein after
cord clamping at delivery from each subject and kept in EDTA-
treated tubes. All samples were processed within 1 hour.
Plasma was separated by centrifugation at 3000 rpm for 10
minutes at 4°C; samples were stored immediately at -80°C in
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aliquots such that freeze-thawing was minimized. Samples
were transported in dry ice for the metabolomics analysis.
Preparation of neonatal serum samples for metabolomic
analysis by 1H-NMR was carried out according to established
protocols [31,32]. Before analysis, the samples were thawed at
room temperature. 200 µl of sample was mixed with 400 µl of
0.9% saline solution (wt/vol, NaCl in 90% H2O/10% D2O) and
then centrifuged at 11,400 rpm for 5 min at 4°C. 550 µl of the
supernatant was added to a 5 mm NMR tube, kept in ice, and
left at room temperature for 30 minutes before measurement.
Case and control samples were selected for analysis in a
random order.
A preparation of the drugs that were administered to the
mother before or at delivery was obtained for NMR analysis
(100% D2O, 500 µl final volume).
NMR Spectroscopy
All spectra were recorded at 27°C with a Bruker Ultrashield
Plus Avance II 600 MHz spectrometer (Bruker Biospin,
Rheinstetten, Germany) equipped with a 5-mm cryogenically-
cooled TCI probe. For each serum sample Carr-Purcell-
Meiboom-Gill (CPMG) [33] and noesy1D spectra were
acquired. The CPMG relaxation-editing pulse sequence was
collected with a total of 128 accumulations and 32K data points
over a spectral width of 20 ppm. The number of loops was set
to total 40 ms of spin-spin relaxation delay and a 3 s relaxation
delay was included between FIDs during which water
irradiation was applied to suppress the H2O signal. 1H noesy1D
spectra were collected using 128 scans, 32K data points, 20
ppm of spectral width, 4 s relaxation delay and 10 ms of mixing
time. Water presaturation was applied during both relaxation
and mixing times. For both experiments a line broadening of
1.0 Hz was applied to the FID which was zero-filled to double
the number of Fourier domain points. Spectra were phased
manually and the baseline corrected automatically using
TopSpin (v. 1.3, Bruker BioSpin, Rheinstetten, Germany).
Chemical shifts were referenced internally to the CH3
resonance of alanine at 1.47 ppm. To aid in metabolite
identification 2D J-resolved (8 transients and 80 increments),
1H,1H-TOCSY and 13C-HSQC experiments were acquired for
selected samples, using 256-512 increments, 32-128 transients
and 1.5 s for relaxation delay. For reference and possible
interferences in metabolite identification, 1H NMR spectra in
100% D2O (32 scans, 32K data points, 14 ppm of spectral
width) were recorded for all the maternal drugs supplied.
Data processing and statistical analysis
Each NMR spectrum was used to construct data matrices for
the statistical analysis by dividing it (from 10.0 to 0.0 ppm) into
buckets of fixed (0.05 ppm) or variable sizes that were
integrated using Amix (v. 3.9.7, Bruker BioSpin, Rheinstetten,
Germany). The water resonance region (5.15-4.40 ppm) was
excluded from the analysis. Buckets were normalized to the
sum of total spectral intensity to minimize potential differences
in concentration between samples. The identification of
metabolites was performed through a combination of 1H/13C
chemical shifts, J-couplings, TOCSY NMR data and their
comparison to metabolite NMR parameters described in
literature references 34,35. For the quantification of selected
metabolites, the region or regions corresponding to their NMR
signals in the CPMG spectra were integrated. The areas in
between the relevant regions were also integrated to fully cover
the spectral width of the 1H (0-10 ppm) with the exception of
the water signal region (4.40-5.15 ppm) that was conveniently
excluded. The integrated spectrum was then normalized to
total area. Results were presented as mean ± standard error of
the mean (s.e.m.). Statistical significance of the data was
determined using the non-parametric Mann-Whitney U test or
ANOVA (Tukey-Kramer post hoc test) where appropriate. P-
values < 0.05 were considered to be statistically significant.
Multivariate data analysis was performed using SIMCA-P+ v.
12.0 (Umetrics AB, Umeå, Sweden). Data were scaled using
the Pareto method (each value divided by the square root of
the standard deviation of each variable), which is normally the
best choice in the case of spectroscopic data as it decreases
the relative importance of highly abundant metabolites but at
the same time preserves data structure. Mean centering was
applied to the scaled data. Unsupervised principal components
analysis (PCA) was used for the overview of individual classes
and all classes jointly, to observe clustering or separation
trends and for the identification of outliers. PCA loading plots
were used to identify metabolites responsible for any
separation observed. Supervised multivariate analysis was
carried out with Partial Least Squares Discriminant Analysis
(PLS-DA) and orthogonal PLS-DA (OPLS-DA). Evaluation of
the PLS/OPLS-DA models was performed using the goodness-
of-fit parameter R2Y (variation in class membership explained
by the model) and the predictive ability parameter Q2
(goodness of prediction, calculated by 7-fold internal cross-
validation). Models were externally validated by building a
model with 2/3 of the data set and predicting the remaining 1/3
in turn, using Fisher’s probability as quality probe of the
classification (<0.01 generally considered a good prediction).
Classification results were used to define True Positives (TP),
True Negatives (TN), False Positives (FP) and False Negatives
(FN) and therefore calculate as percent sensitivity [TP/(TP +
FN) × 100] and specificity [TN/(TN + FP) × 100]. The CV-
ANOVA (Analysis Of Variance testing of Cross-Validated
predictive residuals) included in SIMCA was also used for
assessing the reliability of the PLS/OPLS models. P-values
(likelihood of obtaining such a classification by chance) lower
than 0.05 were indicative of a significant model. In those OPLS
models showing clear separation between classes in the score
plots, the metabolites responsible for the separation were
identified from the loading and the predictive S-plots
(combination of modelled covariance and modelled correlation
in a scatter plot). Those variables presenting high magnitude
and reliability in the S-plot and adequate confidence intervals in
the loading plot were further investigated for putative biomarker
identification.
Student’s t test for independent samples and Pearson’s X2 or
Fisher’s exact tests were used to compare quantitative and
qualitative clinical and demographic data respectively using
SPSS statistical software, version 17.0 (SPSS for Windows,
SPSS Inc, Chicago, IL, USA). A p value < 0.05 was considered
statistically significant.
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Results
Study populations
From the initially selected samples, 3 obtained from early
IUGR cases and 1 AGA sample from the late subset had to be
excluded due to the detection of sample contamination at the
moment of aliquotation (3) and the repeal from the parents to
be included in this study (1), leaving 20 cases vs. 23 controls in
the early subset and 56 cases vs. 55 controls in the late subset
for metabolomic analysis.
Table 1 shows the clinical characteristics of the early IUGR
vs. AGA comparison (early subset). Early IUGR group shows
an increased rate of preeclampsia and caesarean section
delivery, with similar rates of neonatal acidosis, abnormal
Apgar score at 5 minutes and maternal steroid administration.
Maternal drug administration in this subset was recorded and
shown in Table S1. Administration of MgSO4 for the treatment
of severe preeclampsia was significantly higher in early IUGR
patients. Administration of antibiotics (amoxicillin-clavulanic,
penicillin, erythromycin, ampicillin and gentamicin were most
commonly used) and tocolytic agents (ritodrine, nifedipine or
atosiban as most commonly used) as a consequence of
premature rupture of membranes (PROM) and preterm labour
were significantly higher in preterm controls.
Tables 2 to 4 show clinical characteristics of the late IUGR
vs. controls comparison (late subset with and without brain
vasodilation). Late IUGR shows an increased rate of maternal
smoking status at booking, with similar perinatal results to their
AGA counterparts. Maternal drug administration in the late
Table 1. Maternal and neonatal clinical characteristics of
the study group: Early Subset.
 Early IUGR AGA P
 (N=20) (N=23)  
Maternal age (y) 31.5 ± 5.6 32.3 ± 3.8 0.56
Maternal BMI (kg/m2) 24.1 ± 4.0 22.7 ± 2.7 0.25
Maternal smoking (%) 20.0 34.8 0.28
PROM (%) 5.0 69.6 <.001
Premature labor (%) 20.0 65.2 <.01
Preeclampsia (%) 50 0 <.001
GA at birth 31.7 ± 2.2 31.5 ± 2.4 0.83
Cesarean section (%) 95.0 21.7 <.001
Birth weight (g) 1114.7 ± 383.5 1788.2 ± 445.1 <.001
Weight centile 1.0 ± 2.6 41.0 ± 31.4 <.001
Male/female 9/11 13/10 0.45
Neonatal acidosis* (%) 25 14.3 0.29
Apgar score at 5 minutes <7 (%) 30 8.7 0.07
Lung maturation with steroids (%) 80 69.6 0.43
Days from steroids to delivery 2.69 ± 2.1 2.44 ± 3.3 0.8
Results are expressed as mean ± standard deviation or percentage determined by
Student´s t-test for independent samples, Pearson´s X2 or Fisher´s exact test as
appropriate. y=years; PROM: Premature rupture of membranes; GA: Gestational
age; * Neonatal acidosis defined as umbilical artery pH<7.15 and base excess >
12 mEq/l.
doi: 10.1371/journal.pone.0080121.t001
subset was also recorded finding significantly higher rates of
antibiotic administration in controls as shown in Table S2.
NMR analysis
1D CPMG and noesy1D NMR spectra were recorded for
each of the IUGR samples (early, N = 20 and late, N = 56) and
their matched controls (N = 23 and 55 respectively).
Table 2. Maternal and neonatal clinical characteristics of
the study group: Late Subset.
 Late IUGR AGA P
 (N=56) (N=55)  
Maternal age (y) 32.1 ± 5.1 33.1 ± 5.2 0.34
Maternal BMI (kg/m2) 22.7 ± 4.1 24.8 ± 4.6 0.02
Maternal smoking (%) 30.4 10.9 0.01
Preeclampsia (%) 8.9 1.8 0.09
GA at birth 38.3 ± 1.9 38.7 ± 1.8 0.11
Cesarean section (%) 42.9 29.1 0.13
Birth weight (g) 2314.6 ± 286.5 3153 ± 446.3 <0.001
Weight centile 3.8 ± 4.8 48. 2 ± 22.7 <0.001
Male/female 29/27 26/29 0.63
Neonatal acidosis* (%) 9.6 1.9 0.09
Apgar score at 5 minutes <7 (%) 7.1 1.8 0.17
Results are expressed as mean + and standard deviation or percentage
determined by Student´s t-test for independent samples, Pearson´s X2 or Fisher´s
exact test as appropriate. y=years; GA: Gestational age; g= grams; * Neonatal
acidosis defined as umbilical artery pH<7.15 and base excess > 12 mEq/l.
doi: 10.1371/journal.pone.0080121.t002
Table 3. Maternal and Neonatal Clinical Characteristics of
the Study group: Late vasodilated IUGR vs. AGA fetuses.
 Late IUGR AGA P
 (N=18) (N=17)  
Maternal age (y) 33.3 ± 6.3 33.5 ± 3.3 0.91
Maternal BMI (kg/m2) 22.2 ± 4.7 24.1 ± 4.7 0.26
Maternal smoking (%) 27.8 5.9 0.08
Preeclampsia (%) 16.7 5.9 0.3
GA at birth 38.4 ± 1.3 38.7 ± 2.0 0.67
Cesarean section (%) 55.6 29.4 0.11
Birth weight (g) 2373.1 ± 400.7 3117.1 ± 500.2 <0.001
Weight centile 5.2 ± 7.2 46.20 ± 23.9 <0.001
Male/female 12/6 10/7 0.63
Neonatal acidosis* (%) 20 0 0.05
Apgar score at 5 minutes <7 (%) 16.7 0 0.07
Results are expressed as mean + and standard deviation or percentage
determined by Student´s t-test for independent samples, Pearson´s X2 or Fisher´s
exact test as appropriate. y=years; GA: Gestational age; UA: Umbilical artery; g=
grams; * Neonatal acidosis defined as umbilical artery pH<7.15 and base excess >
12 mEq/l.
doi: 10.1371/journal.pone.0080121.t003
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Early-onset IUGR vs. matched AGA newborns (early
subset)
In order to perform the metabolomic analysis of the early
IUGR and matched AGA newborn samples and to spot
possible outliers, preliminary unsupervised PCA was applied to
the full NMR data (43 samples) as well as separately to the
early IUGR cases and AGA control subgroups. Four cases and
one control samples were consistently located in the PCA
scores plot outside the 0.95 Hotelling’s T2 confidence interval.
These five strong outliers required further investigation and
their NMR raw data were examined in detail: One of the above
case samples showed its NMR spectra dominated by very
intense broad signals some of which could be attributed to
lipids. In this particular case, the clinical data presented some
peculiar features (e.g. lowest weight of the early IUGR subset,
400 gr) that suggested severe neonatal distress. Its exclusion
from the following study was therefore justifiable to avoid a
potentially biased analysis. In the case of the control sample
singled out as outlier, it presented very intense glucose signals
that overshadowed the rest of the NMR spectrum, which was
compatible with the maternal diagnosis of suboptimally
controlled gestational diabetes. This prompted us to exclude it
from the study as well. The other three IUGR cases identified
as strong outliers presented several common signals that
largely dominated the spectra: four singlets at 2.55, 2.69, 3.20,
3.61 ppm and two AB patterns at 3.11 and 3.22 ppm split with
the characteristic 2JHH spin coupling. These signals were
identified as exogenous to the biological samples and assigned
to the EDTA (ethylenediaminetetraacetic acid) used as
anticoagulant in the collection tubes[36]. Thus, the intense
singlets at 3.20 and 3.60 ppm correspond to the NCH2CH2N
and NCH2CO protons of free-EDTA, respectively, whereas the
Table 4. Maternal and Neonatal Clinical Characteristics of
the Study group: Late non-vasodilated IUGR vs. AGA
fetuses.
 Late IUGR AGA P
 (N=38) (N=38)  
Maternal age (y) 31.6 ± 4.3 32.9 ± 5.9 0.27
Maternal BMI (kg/m2) 22.9 ± 3.8 25.1 ± 4.6 0.04
Maternal smoking (%) 31.6 13.2 0.05
Preeclampsia (%) 5.3 0 0.15
GA at birth 38.3 ± 1.1 38.8 ± 1.7 0.9
Cesarean section (%) 36.8 28.9 0.46
Birth weight (g) 2287 ± 214.1 3169 ± 426.3 <0.001
Weight centile 3.3 ± 3.3 49.7 ± 22.3 <0.001
Male/female 17/21 16/22 0.7
Neonatal acidosis* (%) 5.4 2.9 0.58
Apgar score at 5 minutes <7 (%) 2.6 2.6 1
Results are expressed as mean + and standard deviation or percentage
determined by Student´s t-test for independent samples, Pearson´s X2 or Fisher’s
exact test as appropriate. y=years; GA: Gestational age; UA: Umbilical artery; g=
grams; * Neonatal acidosis defined as umbilical artery pH<7.15 and base excess >
12 mEq/l.
doi: 10.1371/journal.pone.0080121.t004
pair 2.55/3.11 ppm arises from the Ca-EDTA complex and the
lower intensity signals at 2.69/3.22 ppm from the Mg-EDTA
one. Several other samples were identified as moderate
outliers via the observation residuals detected with the SIMCA-
P+ tool DModX (distance to model), but in each case the
deviation could be attributed to intense signals from a particular
metabolite. Furthermore, no unusual characteristics were
associated with the source of these samples or their mothers
that could justify their exclusion from the analysis and they
were therefore retained for the statistical study. After the
removal of the five strong outliers, the PCA scores plot for the
early subset data showed a reasonable separation between
IUGR cases and controls (R2= 0.63; Q2= 0.37 for the first two
components; Figure 1a): Controls are positioned in the upper
left part of an imaginary line that crosses the scores plot
diagonally, whereas most early-onset IUGR cases are located
in the lower right section. The SIMCA P+ loadings plot (Figure
1b) provided qualitative information about which variables (i.e.
NMR buckets) were responsible for the class separation
observed in the PCA. For this particular model, the NMR
signals that primarily contributed to the clustering of the IUGR
cases were mainly located between 0.80-1.35 ppm (appearing
on the right half of the loadings plot), an NMR region
characteristic of lipids, lactate and the methyl groups from
amino acids such as valine, leucine, isoleucine and threonine.
The differentiation of the control samples arises from NMR
buckets in the region 3.20-4.00 ppm (Figure 1b, left half), which
correspond to metabolites like α/β-glucose or the alpha and
beta hydrogen atoms of most amino acids. Likewise, a bucket
at 5.22 ppm attributable to the H1 of α-glucose, also
contributed significantly to the discrimination of the control
samples. Therefore, a qualitative interpretation of the loadings
plot pointed to glucose as a relevant metabolite in the early
IUGR cases/controls differentiation.
The PCA was also applied to examine the influence in the
score plot distribution of the maternal and neonatal clinical
characteristics of the study group (Table 1). Thus, samples
were labelled in a discrete way (0, 1) for variables such as
smoking, PROM, premature labour, preeclampsia, caesarean
vs. vaginal delivery, gender, neonatal acidosis and abnormal
Apgar score. Subgroups were created such that they covered
the whole sample range for those characteristics represented
by a continuous variable (maternal age, BMI, GA at delivery,
birth weight). However, no sample clustering or group
differentiation was observed for any of the above clinical
characteristics, except for the way of delivery, which showed a
similar separation to that observed between cases and
controls. This trend is easily explained since over 95% of early
IUGR cases were delivered by caesarean section compared to
21.7% of the matched controls. The potential bias caused by
the administration of maternal drugs was also considered on
the PCA analysis, but no related sample discrimination was
observed.
The NMR data from the early subset was further examined
through supervised multivariate PLS-DA, where case/control
class membership is defined with the discrete variable Y. This
analysis produced a significant separation between the two
groups as observed in the corresponding scores plot (Figure
Metabolomic Profile in IUGR
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Figure 1.  Multivariate statistical analysis of early IUGR.  (a) PCA scores-plot of the 1H-CPMG spectra from controls (N = 22, red
dots) and cases (N = 16, black squares). The first two principal components, PC1 and PC2, explain 42 and 20% of the variation
respectively. (b) PCA loadings of the 1H-CPMG spectra displaying the correlated structure of the variables. Selected loadings are
labelled with the midpoint of the corresponding NMR bucket (in ppm). The buckets responsible for the case/control differentiation
are those separating away from the central cluster and in the same direction of the case/control samples observed in the
corresponding PCA scores plot in (a).
doi: 10.1371/journal.pone.0080121.g001
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2a). Class separation was moderately improved in the OPLS-
DA model (Figure 2b), presenting goodness-of-fit R2Y = 0.79
and goodness-of-prediction Q2 = 0.58 (Q2 > 0.5 generally
considered a good model in metabolomics) (i.e. the model
explains 79% of the variation between cases and controls with
a predictive ability of 58%). Several validation tests were
applied to the model for quality and prediction measurement
(Table 5) that confirmed its robustness.
The metabolic information regarding the separation of case/
control classes in the OPLS was extracted via SIMCA’s S-plot
and loadings plot. The S-plot represents an S-shaped
distribution of the NMR buckets (Figure 3a) that allows a quick
visualisation of the OPLS discriminant analysis model for two
classes. The axes from the predictive component, p[1] and
p(corr)[1], represent the magnitude (modelled covariation) and
reliability (modelled correlation) respectively. In spectroscopic
data the magnitude of the signal is important since low
magnitude peaks are close to the noise level and present a
higher risk for spurious correlation. Potential good biomarkers
would be represented by buckets showing simultaneously high
effect and low uncertainty, that is, high reliability (very high or
very low p(corr)[1]). Therefore, NMR buckets located at the
tails of the S are the most attractive as they present high
magnitude and high reliability. The S-plot corresponding to the
early subset presents several variables (=NMR buckets) at
both tails of the S. Those on the left correspond to metabolites
that see their levels increased in the control samples (the
controls are also located on the left side of the OPLS scores
plot, Figure 2b), while the variables on the right correlate with
metabolite levels increased in the early cases (located on the
right side of the OPLS).
A representation of the effect that each bucket produces on
the case/control separation is achieved in the OPLS-DA
loadings plot depicted as a column plot (Figure 3b). The
variables are ordered as in the original NMR spectrum and
those columns presenting the largest positive/negative
differences correspond to those metabolites contributing most
to the class separation. In the early subset there are marked
differences between cases and controls. Positive columns
correlate with metabolites increased in the case subjects and
negative ones correspond to metabolites increased in the
controls. The reliability of each contribution is evaluated by
jack-knifed confidence intervals (not shown in the figure).
Those buckets that showed both large contribution and
reliability in the S-plot/loadings plot were located in the NMR
spectrum and analysed. The metabolites contributing to those
buckets were identified via NMR through a combination of their
1H and 13C chemical shifts, 1H-1H coupling constants and spin
system patterns obtained from 2D 1H,13C-HSQC, J-res and
TOCSY experiments. The buckets presenting the largest
increases when cases are compared with controls were
correlated with various lipid molecules, whereas the highest
metabolite reductions were observed for buckets related to α/β-
glucose. In order to obtain a more precise evaluation of these
variations, the NMR signals from metabolites identified as large
contributors to the case/control separation were re-integrated
accurately in the CPMG spectrum using variable-length bucket
regions. Mean integrals + s.e.m. values were calculated
separately for cases and controls, and their relative amounts
compared (Table 6). The NMR signals corresponding to lipid
molecules presented significantly higher levels (up to 75%
increase) for the early IUGR cases compared to the levels
shown by the controls. Among these variations the largest
changes were observed for signals at 1.26 ppm (LDL+VLDL),
1.56 ppm (VLDL, triglycerides, CH2-CO), 2.20 ppm
(triglycerides, CH2-CO) and 5.23-5.33 ppm (unsaturated lipids)
(Figure 4a). Another signal that appears more intense in the
IUGR subject samples (64% increase) is that corresponding
with the methyl of ketone groups at 2.21 ppm (acetone/
acetoacetate). More modest but statistically significant
increases (aprox. 15%) are observed for creatine and
glutamine. Regarding metabolite reductions, the levels of
glucose are decreased (NMR signals at 5.22 and 3.90-3.40
ppm) for early IUGR cases compared to controls, with an
average negative variation of 25%. Similar metabolite
reductions are observed for choline and slightly lower for
phenylalanine. A particular case was observed for lipid signals
corresponding to VLDL and LDL in the region around 0.85 ppm
(Figure 4b). This broad signal is contributed by both kinds of
lipoprotein, but the resonance overlap does not allow a precise
discrimination into two differentiated buckets. Although the %
variation between cases and controls is very small when the
whole region (0.90-0.79 ppm) is taken into account (4%), it can
be easily discerned that the VLDL (left side) contribution is
increased in IUGR early cases, whilst LDL levels (right) are
higher in the control samples. NMR lipid signals are inherently
broad and consequently partially suppressed in the CPMG
experiment. However, any possible reduction in signal intensity
caused by relaxation effects would be consistent across
samples; thus, relative changes in concentration values would
be still relevant.
Other metabolic differences have been reported in previous
IUGR studies [25,26,37], involving molecules such as arginine,
proline, glycine, serine, threonine, myo-inositol, sarcosine and
creatinine. In our early IUGR data study, NMR buckets
associated with these metabolites did not show any remarkable
variation or statistically significant changes.
Late-onset IUGR vs. matched AGA newborns (late
subset)
The same protocol described above was applied for the
examination of the metabolic profile of the late subset
comparing 56 late IUGR vs. 55 AGA controls.
An initial unsupervised PCA of the whole late subset did not
result in any obvious discrimination or clustering between
cases and controls. Although several strong outliers were
identified, only five samples were justifiably excluded from
further analyses: a case sample with deficient water
suppression in the NMR spectra that affected the base line of
the whole spectrum and four controls that presented the same
contamination found in some samples of the early subset. The
PCA of the late subset excluding these five outliers (Figure S1)
did not render any improvement in class separation or
clustering of samples. The elimination of additional outliers
from the analysis did not show any separation enhancement
(PCA not shown).
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Figure 2.  Multivariate statistical analysis of early IUGR.  (a) PLS-DA (R2Y = 0.64; Q2 = 0.54; p-value = 2.8E-05) and (b) OPLS-
DA (R2Y = 0.79; Q2 = 0.58; p-value = 0.00052) scores plots of the 1H-CPMG spectra from controls (N = 22, red dots) and cases (N =
16, black squares). Samples from cases and controls were defined as two different classes.
doi: 10.1371/journal.pone.0080121.g002
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Analogously to the analysis carried out on the early subset,
the PCA was also applied to the late samples for the
examination of the maternal and neonatal clinical
characteristics, but no clustering or group differentiation was
observed.
The subsequent supervised PLS/OPLS discriminant analysis
on the late subset samples showed a uniform overlap between
case/control classes (Figure S2a and Figure S2b), presenting
very low goodness-of-fit and prediction values and poor
external validation parameters (Table 5). A variable selection
process was then applied by first removing from the analysis
buckets from the NMR spectra that did not present any signal,
and second by only retaining those variables that showed
reliable (acceptable confidence-intervals) contributions. The
resulting models did not improve the fitness and prediction
values obtained with the full range of NMR variables, indicating
that there was not a clear separation between cases and
controls in the late subset. The metabolites identified in the
early subset as relevant were also evaluated here; same
metabolite variations as those found in the early subset were
detected, but to a lesser extent (Table 7). Thus, an increase of
lipid concentration was again observed for the IUGR cases,
although in a lower variation (up to 20%) than in the early
subset. Glucose levels were again slightly decreased (-5.8%)
but the result could not be considered statistically significant.
Other metabolites found relevant in the early subset study
(acetone/acetoacetate, creatine, phenylalanine) did not present
any significant difference in the late subset analysis. Although
with relatively modest numbers, a particular case is presented
by the amino acid glutamine which showed a 14.8% increase in
the early IUGR cases, but a decrease of nearly 10% for the late
IUGR subjects compared to the control samples. Similar
Table 5. IUGR multivariate statistical analysis parameters
and model validation values.






























0.59 0.47 0.32 0.019 77.8 75 0.0027
a p values were obtained from a two-way analysis of variance (ANOVA). b
Classification results were used to define True Positives (TP), True Negatives
(TN), False Positives (FP) and False Negatives (FN) and therefore calculate as
percent sensitivity [TP/(TP + FN) × 100] and specificity [TN/ (TN + FP) × 100]. c
Probability of a particular classification result occurring by chance and is satisfied
when p<0.05 for 95% confidence. VD: Vasodilated.
doi: 10.1371/journal.pone.0080121.t005
reductions in metabolite levels were also observed for choline,
alanine, valine, tyrosine and leucine.
Late samples were also divided in two subgroups based on
the presence of brain vasodilation (Tables 3 and 4). 18 brain
vasodilated late-onset IUGR cases matched with 17 AGA
controls showed in the PCA some degree of separation
between cases and controls (Figure 5a), with the larger portion
of the cases located in the upper part of the score plot while the
controls were found in the lower region. The multivariate
supervised OPLS-DA confirmed these results and showed a
discrimination between classes, although the model values
could not be considered optimal (Figure 5b; Table 7: R2Y =
0.47; Q2 = 0.32). The metabolites causing the case/control
separation were identified via the S- and loading plots obtained
from the OPLS-DA model. Buckets with significant increases in
the case samples were associated with lipids (Table 8;
2.25-2.18 ppm: CH2O; 1.56 ppm: CH2-CH2CO; 1.26 ppm:
VLDL/LDL). In addition, decreases in the amounts of the amino
acids choline, phenylalanine, tyrosine and valine were
observed for the vasodilated late-onset IUGR cases relative to
the control samples (Figures 6 and 7).
The multivariate analysis of the 38 non-vasodilated late-
onset IUGR with 38 matched AGA did not produce a clear
differentiation between cases and controls, presenting non-
significant goodness-of-fit and prediction values. The
comparison of metabolic levels rendered small positive
variations for lipids/VLDL (Table 9, up to 17%) and minor
reductions of the metabolites choline, glutamine, valine, leucine
and alanine (Figures 6 and 7).
Discussion
This study provides evidence on the existence of distinct
metabolomic patterns of different clinical subsets in human
IUGR. Using 1H NMR, several metabolites were identified
allowing a clear discrimination between IUGR and AGA
samples, consisting in important increases in lipids,
acetoacetate and decreased glucose levels. Amino acid
patterns showed significant changes in IUGR cases and
among the study subgroups, supporting the existence of
potential pathophysiological differences between early-onset
and late-onset IUGR cases with and without signs of brain
vasodilation.
One of the major findings in our work was the altered lipid
profile. Abnormal lipid metabolism was detected in both early
and late-onset IUGR samples, particularly at the expense of
unsaturated lipids and VLDL. Our results are in agreement with
previous reports of altered, pro-atherogenic lipid and
cholesterol metabolism in IUGR fetuses [38–40]. These
differences in the clinical setting have been tested in animal
model studies obtaining similar results [41]. Furthermore,
triglycerides (TGs) were found to be increased up to 33% in
early-onset IUGR cases when compared to controls, which is
consistent with previously published evidence [39,42–44]. The
relevance of this finding relies on the fact that TGs act as an
independent predictor of coronary artery disease which could,
in association with the other lipid alterations found in this
condition, potentially explain the proposed increased risk of
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Figure 3.  Early IUGR.  (a) Representation of the OPLS-DA loadings in the form of an S-plot: the magnitude of each loading, p, is
represented against its reliability p(corr).Those loadings (NMR buckets) showing high magnitude and reliability are encircled. (b)
OPLS-DA loadings plot displayed as columns. Chemical shift is represented against magnitude of the loading. Reliability is
evaluated by jack-knife 95% confidence intervals (not shown in the figure for clarity reasons). Positive loadings correspond with
metabolites present in increased amounts in the case subjects; negative loadings correspond with metabolites in lower
concentrations.
doi: 10.1371/journal.pone.0080121.g003
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cardiovascular disease in later life in IUGR cases [42]. As to
the nature of the underlying pathophysiological mechanisms
involved in these findings, abnormal lipid metabolism in IUGR
could be explained by both chronic exposure to hypoxia and
undernutrition: Hypoxic damage can induce significant
derangements in plasmatic lipids during perinatal life resulting
in hyperlipidemia [45] and also increased cholesterol esters in
hypoxia-cultured placental tissue [46]. In addition, increased
cholesterol levels are associated to starving conditions such as
anorexia nervosa [47,48]. Moreover, reports from animal model
in undernourished conditions show an increase of free fatty
acids in arterial plasma and an impaired clearance of TG-rich
lipoproteins [49]. All subgroups of IUGR were associated with
significant changes in lipids, but there was a gradation of
severity with more marked changes in severe cases (Figure 6).
The presence of significant differences also in non-vasodilated
late-onset IUGR cases supports the notion that at least a large
proportion of these fetuses are not constitutionally small.
In agreement with previous studies [41,50–53], early-onset
IUGR showed significant decreases in glucose levels and
significant increases in ketones. A non-significant trend was
observed for late IUGR subgroups. Differences between early
and late onset forms should be interpreted in line with previous
findings in which glucose levels were inversely correlated to the
clinical severity of IUGR [50,51,54]. As to the mechanisms
involved in these findings, it is known that growth restricted
fetuses maintain lower glucose concentrations to increase
transplacental glucose gradient, which will keep the glucose
uptake across the placenta of limited size [51]. Additionally,
under growth restricted conditions glycolytic processes are
enhanced by hypoxia-inducible factors [46], resulting in a more
pronounced metabolic-substrate deficient situation with an
increased ketogenesis.
Specific changes in the amino acid profile provided an
interesting insight which suggested important differences
among the clinical subsets studied. Glutamine levels were
found to be increased in early IUGRs as compared with
matched controls. This finding is in line with previous studies in
very low birth weight and also in early-IUGR preterm neonates
[25,53]. Glutamine concentration in fetal blood depends on the
transfer from maternal blood but also on placental synthesis
[55]. Fetal glutamine is next to glucose as one of the main
sources of cellular energy in fetal life [55]. It also plays a key
role in fetal neurodevelopment being a precursor of alpha-
amino butyric acid, a neurotransmission inhibitor [55].
Increased glutamine levels in severe IUGR could be explained
by the inherent hypercatabolic status of this condition, in
association to decreased glucose levels [56,57]. This lack of
energy substrates may convey to increase glutamine supply to
the fetus through different mechanisms [53]. When the different
late-IUGR subsets were considered in regard to glutamine
levels, thought-provoking differences were found: while
vasodilated late-IUGR cases did not show any significant
change, there was a significant decrease in the non-
vasodilated late-IUGR cases (Figure 7). The explanation for
this is unclear. However, this finding could be understood in the
light of other pathologies with decreased glutamine levels such
as in chronic stress conditions [58,59]. It is tempting to
speculate that similar mechanisms may be involved here;
whereas an overexposure to glucocorticoids is involved in
chronic stress, it may as well play an important role in this
clinical subform of IUGR. Indeed, increased corticosteroid
Table 6. Relative amounts of most significant metabolites in early-onset IUGR samples compared to control samples.
metabolite 1H chemical shift (ppm) assignment mean+sem (cases)a mean+sem (controls)a p-valueb % variationc
unsaturated lipids 5.35-5.24 =CH-CH2-CH 1.44E-02 ± 9.08E-04 9.83E-03 ± 3.82E-04 <0.0001 46.6
α/β-glucose 5.22. 3.89-3.40 H1-H6 2.41E-01 ± 1.70E-02 3.22E-01 ± 2.03E-02 0.0266 -25.1
lipid 2.82-2.70 C=CCH2C=C 9.60E-03 ± 4.25E-04 7.23E-03 ± 2.77E-04 0.0002 32.8
lipid 2.25-2.18 CH2CO 2.40E-02 ± 1.89E-03 1.37E-02 ± 4.84E-04 <0.0001 75.8
acetone/ acetoacetated 2.21 CH3CO 2.23E-02 ± 2.45E-03 1.36E-02 ± 1.25E-03 0.0008 63.6
lipid (VLDL) 1.56 CH2CH2CO 1.35E-02 ± 1.05E-03 7.72E-03 ± 2.95E-04 <0.0001 75.0
lipid (VLDL+LDL) 1.30-1.20 CH2 1.17E-01 ± 9.03E-03 7.61E-02 ± 2.78E-03 <0.0001 53.6
lipid (VLDL+LDL) 0.88-0.78 CH3 6.46E-02 ± 3.03E-03 6.21E-02 ± 2.46E-03 NS 4.0
triglycerides 5.18 CHOCOR 3.97E-03 ± 2.40E-04 2.98E-03 ± 2.15E-04 0.0023 32.9
myo-inositol 3.28 H5 7.59E-03 ± 4.54E-04 6.67E-03 ± 3.18E-04 NS 13.8
choline 3.20 N(CH3)3 1.74E-02 ± 1.38E-03 2.34E-02 ± 7.25E-04 0.0001 -25.7
creatine 3.92 CH2 2.15E-02 ± 9.54E-04 1.85E-02 ± 5.79E-04 0.011 16.6
glutamine 2.44 γ-CH2 1.85E-02 ± 8.71E-04 1.62E-02 ± 5.52E-04 0.0141 14.8
phenylalanine 7.43-7.29 aromatics 2.34E-03 ± 6.57E-05 2.77E-03 ± 1.20E-04 0.0246 -15.3
tyrosine 6.88/7.18 aromatics 3.55E-03 ± 1.32E-04 3.82E-03 ± 2.00E-04 NS -7.0
valine 1.03/0.97 CH3 4.69E-02 ± 2.05E-03 4.92E-02 ± 1.72E-03 NS -4.7
leucine 0.95 CH3 3.12E-02 ± 9.05E-04 3.13E-02 ± 1.03E-03 NS -0.3
alanine 1.47 CH3 1.16E-02 ± 6.32E-04 1.10E-02 ± 3.17E-04 NS 5.3
a Integral values are normalised to the sum of total spectral intensity. b p values were calculated by Mann-Whitney U test. NS=Non-significant result (p value >0.05). c
Variation of the relative amount of metabolite in subject cases relative to controls: positive value indicates an increase and negative value a decrease in the cases. d
Overlapped with lipid signals. VLDL: Very low density lipoprotein. LDL: Low density lipoprotein.
doi: 10.1371/journal.pone.0080121.t006
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Figure 4.  1H NMR of fetal serum.  (a) Representative 1H-CPMG NMR spectrum of fetal serum from an IUGR early case at 600
MHz and 27°C. Insets: expansions of the aliphatic region (0.5-4.5 ppm) and assignment of the most abundant metabolites. LDL: low
density lipoproteins; VLDL: very-low density lipoproteins; NAC: acetyl signals from glycoproteins. (b) Superimposed expansion of
the VLDL/LDL CH3 region (0.90-0.78 ppm) from the 1H-CPMG NMR spectra, showing control (red lines) and case (black lines)
samples from the early subset.
doi: 10.1371/journal.pone.0080121.g004
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transfer to the fetus has long been suggested as a potential
pathogenic pathway of IUGR in humans [60,61].
Increased creatine levels in early IUGR could be interpreted
as well by a metabolic-substrate deficient condition. Creatine is
an essential metabolite for energy metabolism through the
production of ATP and increased levels have been reported in
preterm IUGR neonates [62] in IUGR-induced gilts [41].
Phenylalanine and tyrosine levels were decreased similarly
in early and late vasodilated IUGR cases. Tyrosine is
synthesized from the essential amino acid phenylalanine.
Previously published results from in vitro and in vivo studies on
phenylalanine in IUGR conditions have yielded controversial
information [25,41,46,63], which could be explained by
important differences in the selection of IUGR cases included.
In general, studies focusing on early-onset severe IUGR cases
showed decreased phenylalanine levels [63], attributed to an
altered placental transport, plausibly resulting from a
“damaged” placental tissue and the inherent hypercatabolic
state in IUGR [41,63]. The observation of a similar decrease in
phenylalanine in the group of vasodilated late-IUGR fetuses
could support the hypothesis that this clinical subset represents
a late form of placental insufficiency [16]. The implications of
decreased phenylalanine and tyrosine as neurotransmitter
precursors in these clinical forms, both associated with adverse
neurological outcome [10,64–66], deserves further
investigation. Finally, non-vasodilated late IUGR was
associated with a remarkably distinct response in relation with
phenylalanine and tyrosine suggesting a more prominent role
of other mechanisms as discussed above.
Leucine and valine were significantly decreased in both
forms of late IUGR regardless the presence or absence of
brain vasodilation, but not in early IUGR. Valine and leucine,
together with isoleucine, are defined as branched-chain amino
acids (BCAA). The data goes in line with other reports from late
IUGR fetuses in which all BCAA were decreased [67]. Our
observations suggest that changes in these amino acids could
be a characteristic feature of IUGR late in gestation. Again,
diverse pathways might concur to explain these results. On one
hand, plasmatic concentrations of BCAA are prominently
reduced during chronic malnutrition [68,69]. However,
exposure to increased glucocorticoids has similar effects to
food restriction on BCAA aminotransferase and other enzymes
regulating the catabolism and plasma concentrations of these
amino acids [70]. The reason for the lack of changes in BCAA
in early-onset IUGR is unclear. Previous studies suggest that
BCAA could be transiently increased or remain unchanged
during states of severe starvation [71], which might help
explain our observations.
Decreased choline concentrations were found in all IUGR
subsets, with a progression across clinical severity in early
(25.7% decrease), vasodilated late (18.7%) and non-
vasodilated late IUGR cases (9%). Choline is an essential
metabolite under a high demand during pregnancy. Large
amounts of this amino acid are delivered to the fetus across the
placenta [72]. Circulating choline has also been reported to be
reduced under malnutrition [73] and reductions in IUGR could
be due to impaired transplacental supply. However, this does
not exclude other pathways, since reduced serum levels have
also been described in response to glucocorticoid therapy and
chronic stress [74]. Choline has a key role in
neurodevelopment, being the precursor of phosphatidylcholine
for myelinization [75]. It has a crucial role in DNA methylation
Table 7. Relative amounts of most significant metabolites in late-onset IUGR samples compared to control samples.
metabolite 1H chemical shift (ppm) assignment mean+sem (cases)a mean+sem (controls)a p-valueb % variationc
unsaturated lipids 5.35-5.24 =CH-CH2-CH 1.41E-02 ± 4.76E-04 1.25E-02 ± 4.11E-04 0.0122 13.6
α/β-glucose 5.22. 3.89-3.40 H1-H6 2.50E-01 ± 1.12E-02 2.65E-01 ± 1.09E-02 NS -5.8
lipid 2.82-2.70 C=CCH2C=C 9.68E-03 ± 2.57E-04 8.59E-03 ± 2.43E-04 0.0016 12.7
lipid 2.25-2.18 CH2CO 2.23E-02 ± 8.35E-04 1.87E-02 ± 6.45E-04 0.0002 19.3
acetone/ acetoacetated 2.21 CH3CO 2.37E-02 ± 1.67E-03 1.99E-02 ± 1.05E-03 NS 19.6
lipid (VLDL) 1.56 CH2CH2CO 1.28E-02 ± 4.75E-04 1.10E-02 ± 3.51E-04 0.0017 16.5
lipid (VLDL+LDL) 1.30-1.20 CH2 1.14E-01 ± 5.00E-03 1.00E-01 ± 3.74E-03 0.027 13.8
lipid (VLDL+LDL) 0.88-0.78 CH3 6.60E-02 ± 1.90E-03 6.53E-02 ± 1.54E-03 NS 1.1
triglycerides 5.18 CHOCOR 3.76E-03 ± 1.47E-04 3.49E-03 ± 2.03E-04 NS 7.7
myo-inositol 3.28 H5 6.74E-03 ± 1.87E-04 6.58E-03 ± 2.17E-04 NS 2.3
choline 3.20 N(CH3)3 1.83E-02 ± 4.68E-04 2.09E-02 ± 5.48E-04 0.0003 -12.1
creatine 3.92 CH2 1.76E-02 ± 4.10E-04 1.78E-02 ± 3.46E-04 NS -1.2
glutamine 2.44 γ-CH2 1.50E-02 ± 4.36E-04 1.66E-02 ± 3.83E-04 0.0124 -9.5
phenylalanine 7.43-7.29 aromatics 2.42E-03 ± 7.33E-05 2.43E-03 ± 2.02E-04 NS -0.2
tyrosine 6.88/7.18 aromatics 3.22E-03 ± 1.07E-04 3.42E-03 ± 2.12E-04 0.007 -5.8
valine 1.03/0.97 CH3 4.37E-02 ± 1.13E-03 4.95E-02 ± 9.58E-04 0.0003 -11.8
leucine 0.95 CH3 3.20E-02 ± 5.74E-04 2.95E-02 ± 6.27E-04 0.0174 -7.9
alanine 1.47 CH3 1.05E-02 ± 2.77E-04 1.13E-02 ± 3.24E-04 0.035 -6.9
a Integral values are normalised to the sum of total spectral intensity. b p values were calculated by Mann-Whitney U test. NS=Non-significant result (p value >0.05). c
Variation of the amount of metabolite in subject cases relative to controls: positive value indicates an increase and negative value a decrease for the cases. d Overlapped
with lipid signals. VLDL: Very low density lipoprotein. LDL: Low density lipoprotein.
doi: 10.1371/journal.pone.0080121.t007
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Figure 5.  Multivariate statistical analysis of the late subset with cases showing increased brain vasodilation.  (a) PCA
scores plot of the 1H-CPMG spectra from controls (N = 17, red dots) and cases (N = 18, black squares). The first two principal
components, PC1 and PC2, explain 43 and 20% of the variation, respectively. (b) OPLS-DA scores plot of the 1H-CPMG spectra
from the same subset as (a). Samples from cases and controls were defined as two different classes. R2Y = 0.47; Q2 = 0.32; p-value
= 0.019.
doi: 10.1371/journal.pone.0080121.g005
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and hence in epigenetic mechanisms [72], which form the basis
of fetal programming. Experimental [72,75] and human [76]
studies suggest that choline-deficient conditions lead to
abnormal cognitive development. Interestingly, all forms of
IUGR, even those late-onset forms without signs of brain
vasodilation, have been associated with long term
neurodevelopmental and cardiovascular programming [77,78].
The potential role of choline deficiency in these long term
effects deserves further investigation.
The main strengths of our study should be highlighted:
Firstly, cohorts were constructed prospectively and cases were
matched with controls by gestational age to avoid potential
biases [40,50]. Also, clinical classification based on early and
late IUGR is in agreement with our current practice and as
shown in this study, the potentially different mechanisms
involved in each clinical subform are worth this separation.
However, we acknowledge that this study has several
limitations. As expected, increased rates of preeclampsia and
caesarean section delivery were present in the early IUGR
cases. Regarding the first, this concurrence can be explained
due to the known common ethiopathogenic mechanisms
involved in preeclampsia and severe IUGR [43]; however, this
clinical feature was not associated to any sample clustering or
group differentiation based on the PCA that was performed to
examine the influence of this variable. Furthermore, literature
shows how the additional diagnosis of preeclampsia does not
affect lipid alterations found in IUGR [39]. On the other hand,
higher caesarean delivery rate in early IUGR can be explained
due to a usually undeferrable need to end the pregnancy at a
distant gestational age from term with unfavourable conditions
for a vaginal delivery. Natural control patients for this condition
are those born prematurely due to preterm labour, which
favours vaginal delivery. Therefore, early IUGR is inevitably
associated to a high rate of cesarean delivery. However it
should be noted that samples from the late subset, with similar
caesarean section rates between cases and controls, showed
similar but less-severe metabolic differences than the early
subset, suggesting that metabolic differences may be related to
the disease itself and not to the mode of delivery. So, we
acknowledge that residual metabolic effects from the additional
diagnoses of preeclampsia or caesarean delivery to IUGR can
not be completely ruled out. Also, we acknowledge that all
clinical classifications are subject to bias and an important
overlapping among cases is inevitably present. In addition, we
used here three subsets of IUGR but future research might
identify further subgroups either among early or late-onset
forms of IUGR. For instance, it is likely that among late-onset
there are constitutionally small fetuses which are not the result
of any pathological condition. We expect that future studies will
extend our observations to improve the characterization of
pathogenic pathways leading to the common problem of
restricted intrauterine growth.
To conclude, IUGR is not associated with a unique metabolic
profile, but important changes are present in different clinical
subsets used in research and clinical practice. Besides major
and common changes found in most IUGR cases, such as
increased lipids and decreased glucose, amino acid changes
may bring insight to specific mechanisms involved in this
disease. It seems that early- and late vasodilated IUGR share
features with respect to some amino acid changes that are not
observed in late non-vasodilated fetuses. These results provide
support to the hypothesis that early-onset and late-onset
Table 8. Relative amounts of most significant metabolites in brain vasodilated late-onset IUGR compared to control samples.
metabolite 1H chemical shift (ppm) assignment mean+sem (cases)a mean+sem (controls)a p-valueb % variationc
unsaturated lipids 5.35-5.24 =CH-CH2-CH 1.35E-02 ± 5.33E-04 1.21E-02 ± 7.16E-04 NS 11.9
α/β-glucose 5.22. 3.89-3.40 H1-H6 2.54E-01 ± 1.81E-02 2.76E-01 ± 1.87E-02 NS -8.1
lipid 2.82-2.70 C=CCH2C=C 9.32E-03 ± 2.82E-04 8.73E-03 ± 4.07E-04 NS 6.7
lipid 2.25-2.18 CH2CO 2.22E-02 ± 8.94E-04 1.79E-02 ± 8.10E-04 0.0006 24.0
acetone/ acetoacetated 2.21 CH3CO 2.58E-02 ± 3.76E-03 1.83E-02 ± 1.46E-03 NS 41.0
lipid (VLDL) 1.56 CH2CH2CO 1.28E-02 ± 5.26E-04 1.04E-02 ± 4.58E-04 0.0031 22.5
lipid (VLDL+LDL) 1.30-1.20 CH2 1.10E-01 ± 5.23E-03 9.32E-02 ± 4.74E-03 0.0232 18.0
lipid (VLDL+LDL) 0.88-0.78 CH3 6.26E-02 ± 1.82E-03 6.42E-02 ± 1.82E-03 NS -2.6
triglycerides 5.18 CHOCOR 3.57E-03 ± 2.17E-04 3.37E-03 ± 2.04E-04 NS 5.8
myo-inositol 3.28 H5 6.66E-03 ± 2.40E-04 6.86E-03 ± 3.45E-04 NS -3.0
choline 3.20 N(CH3)3 1.72E-02 ± 7.28E-04 2.12E-02 ± 8.87E-04 0.007 -18.7
creatine 3.92 CH2 1.72E-02 ± 5.57E-04 1.80E-02 ± 6.94E-04 NS -4.6
glutamine 2.44 γ-CH2 1.64E-02 ± 6.83E-04 1.65E-02 ± 7.32E-04 NS -0.3
phenylalanine 7.43-7.29 aromatics 2.39E-03 ± 9.87E-05 2.70E-03 ± 8.97E-05 0.0174 -11.6
tyrosine 6.88/7.18 aromatics 6.32E-03 ± 2.98E-04 7.30E-03 ± 2.59E-04 0.0177 -13.4
valine 1.03/0.97 CH3 4.51E-02 ± 1.70E-03 5.03E-02 ± 1.80E-03 0.0367 -10.2
leucine 0.95 CH3 2.91E-02 ± 1.05E-03 3.23E-02 ± 1.15E-03 NS -9.8
alanine 1.47 CH3 1.09E-02 ± 2.96E-04 1.07E-02 ± 2.29E-04 NS 2.1
a Integral values are normalised to the sum of total spectral intensity. b p values were calculated by Mann-Whitney U test. NS=Non-significant result (p value >0.05). c
Variation of the amount of metabolite in subject cases relative to controls: positive value indicates an increase and negative value a decrease for the cases. d Overlapped
with lipid signals. VLDL: Very low density lipoprotein. LDL: Low density lipoprotein.
doi: 10.1371/journal.pone.0080121.t008
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vasodilated fetuses share a similar pathophysiology with
differences in the timing and severity of the disease
[16,19,78,79]. However, at the same time there are common
features to both late-IUGR subsets, which are not observed in
early-onset IUGR fetuses. Further research is required to
identify the origin of such changes in late-onset IUGR, since as
discussed above, diverse pathways could lead to similar
effects. These results provide grounds for future studies aiming
at characterizing comprehensively specific hormonal and
metabolic alterations underlying different pathophysiological
subsets within the common diagnostic label of intrauterine
growth restriction. Such knowledge is required to advance in
the development of biomarkers and identify therapeutic
approaches.
Figure 6.  - Variation of the relative amount of lipids, glucose and acetone/acetoacetate (ketones) in early IUGR,
vasodilated (VD) late IUGR and non-VD late IUGR cases relative to controls: positive value indicates an increase and
negative value a decrease in the cases.  * represents a statistically significant metabolic variation ( p< 0.05). Unsat.lipids=
Unsaturated lipids. VLDL=Very low density lipoprotein. LDL=Low density lipoprotein.
doi: 10.1371/journal.pone.0080121.g006
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Figure 7.  Variation of the relative amount of amino acids and derivates in early IUGR, vasodilated (VD) late IUGR and non-
VD late IUGR cases relative to controls: positive value indicates an increase and negative value a decrease in the cases.  *
represents significant a statistically metabolic variation (p< 0.05).Phe =Phenylalanine.
doi: 10.1371/journal.pone.0080121.g007
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Table 9. Relative amounts of most significant metabolites in non-vasodilated late IUGR compared to control samples.
metabolite 1H chemical shift (ppm) assignment mean+sem (cases)a mean+sem (controls)a p-valueb % variationc
unsaturated lipids 5.35-5.24 =CH-CH2-CH 1.44E-02 ± 6.49E-04 1.26E-02 ± 5.05E-04 0.0164 14.3
α/β-glucose 5.22. 3.89-3.40 H1-H6 2.48E-01 ± 1.42E-02 2.60E-01 ± 1.35E-02 NS -4.6
lipid 2.82-2.70 C=CCH2C=C 9.85E-03 ± 3.52E-04 8.53E-03 ± 3.05E-04 0.0031 15.5
lipid 2.25-2.18 CH2CO 2.23E-02 ± 1.15E-03 1.90E-02 ± 8.65E-04 0.0136 17.3
acetone/ acetoacetated 2.21 CH3CO 2.28E-02 ± 1.73E-03 2.06E-02.± 1.37E-03 NS 10.8
lipid (VLDL) 1.56 CH2CH2CO 1.29E-02 ± 6.55E-04 1.13E-02 ± 4.65E-04 0.0286 13.9
lipid (VLDL+LDL) 1.30-1.20 CH2 1.16E-01 ± 6.91E-03 1.04E-01 ± 4.95E-03 NS 12.1
lipid (VLDL+LDL) 0.88-0.78 CH3 6.76E-02 ± 2.62E-03 6.58E-02 ± 2.09E-03 NS 2.8
triglycerides 5.18 CHOCOR 3.85E-03 ± 1.90E-04 3.54E-03 ± 2.83E-04 NS 8.5
myo-inositol 3.28 H5 6.77E-03 ± 2.52E-04 6.46E-03 ± 2.74E-04 NS 4.9
choline 3.20 N(CH3)3 1.89E-02 ± 5.83E-04 2.07E-02 ± 6.95E-04 0.0216 -9.0
creatine 3.92 CH2 1.77E-02 ± 5.43E-04 1.77E-02 ± 3.98E-04 NS 0.4
glutamine 2.44 γ-CH2 1.43E-02 ± 5.26E-04 1.66E-02 ± 4.54E-04 0.0009 -13.6
phenylalanine 7.43-7.29 aromatics 2.44E-03 ± 9.76E-05 2.30E-03 ± 2.90E-04 NS 6.0
tyrosine 6.88/7.18 aromatics 3.20E-03 ± 1.32E-04 3.26E-03 ± 2.97E-04 NS -1.7
valine 1.03/0.97 CH3 4.30E-02 ± 1.45E-03 4.92E-02 ± 1.14E-03 0.0007 -12.6
leucine 0.95 CH3 4.30E-02 ± 1.45E-03 4.92E-02 ± 1.14E-03 0.0163 -7.1
alanine 1.47 CH3 1.04E-02 ± 3.79E-04 1.16E-02 ± 4.54E-04 0.0198 -10.6
a Integral values are normalised to the sum of total spectral intensity. b p values were calculated by Mann-Whitney U test. NS=Non-significant result (p value >0.05). c
Variation of the amount of metabolite in subject cases relative to controls: positive value indicates an increase and negative value a decrease for the cases. d Overlapped
with lipid signals. VLDL: Very low density lipoprotein. LDL: Low density lipoprotein.
doi: 10.1371/journal.pone.0080121.t009
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Supporting Information
Figure S1.  Multivariate statistical analysis of the late
subset. PCA scores plot of the 1H-CPMG spectra from controls
(N = 51, red dots) and cases (N = 55, black squares). The first
two principal components, PC1 and PC2 explain 36 and 30%
of the variation, respectively.
(TIF)
Figure S2.  Multivariate statistical analysis of the late
subset. (a) PLS-DA (R2Y = 0.22; Q2 = 0.07; p-value = 0.133,
statistically non-significant) and (b) OPLS-DA (R2Y = 0.30; Q2
=0.17; p-value = 0.005) scores plots of the 1H-CPMG spectra
from the controls (N = 51, red dots) and cases (N = 55, black
squares). Samples from cases and controls were defined as
two different classes.
(TIF)
Table S1.  Maternal drug administration in early IUGR
subset.
(DOC)
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